Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report published on Monday. The brokerage issued a hold rating on the medical research company’s stock.

A number of other research analysts have also recently commented on the company. HC Wainwright restated a neutral rating and set a $1.00 price objective on shares of Cytosorbents in a research note on Tuesday, May 7th. B. Riley restated a buy rating and set a $3.00 price objective on shares of Cytosorbents in a research note on Wednesday, May 15th.

Cytosorbents Price Performance

CTSO stock opened at $0.93 on Monday. The stock has a 50-day moving average price of $0.89 and a two-hundred day moving average price of $1.04. Cytosorbents has a 12-month low of $0.78 and a 12-month high of $4.29. The company has a current ratio of 1.49, a quick ratio of 1.21 and a debt-to-equity ratio of 0.10. The company has a market cap of $50.51 million, a PE ratio of -1.58 and a beta of 0.61.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.12) EPS for the quarter, hitting analysts’ consensus estimates of ($0.12). The company had revenue of $9.79 million for the quarter, compared to analysts’ expectations of $9.78 million. Cytosorbents had a negative return on equity of 129.89% and a negative net margin of 75.07%. During the same quarter in the previous year, the firm posted ($0.17) earnings per share. As a group, research analysts predict that Cytosorbents will post -0.36 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Avenir Corp lifted its stake in shares of Cytosorbents by 4.0% in the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after acquiring an additional 121,294 shares in the last quarter. CM Management LLC lifted its stake in shares of Cytosorbents by 98.8% in the first quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock worth $784,000 after acquiring an additional 410,000 shares in the last quarter. Key Client Fiduciary Advisors LLC lifted its stake in shares of Cytosorbents by 188.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock worth $33,000 after acquiring an additional 22,557 shares in the last quarter. Neuberger Berman Group LLC lifted its stake in shares of Cytosorbents by 19.9% in the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after acquiring an additional 299,103 shares in the last quarter. Finally, Skylands Capital LLC lifted its stake in shares of Cytosorbents by 10.5% in the fourth quarter. Skylands Capital LLC now owns 3,254,213 shares of the medical research company’s stock worth $3,612,000 after acquiring an additional 309,543 shares in the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.